ubiquitin
proteasom
system
up
essenti
regul
myriad
aspect
protein
function
therefor
fundament
import
regulatori
mechan
impact
aspect
cellular
process
inde
malfunct
up
compon
implic
human
diseas
neurodegen
immunolog
disord
mani
cancer
success
proteasom
inhibitor
cancer
therapi
suggest
modul
enzym
ubiquitin
cascad
would
clinic
import
therapeut
benefit
review
summar
advanc
develop
inhibitor
varieti
up
compon
particular
highlight
recent
work
done
protein
engin
ubiquitin
modul
up
novel
approach
may
shed
light
innov
drug
discoveri
futur
ubiquitin
dynam
revers
posttransl
process
initi
discov
proteasom
mediat
protein
degrad
sinc
becom
clear
ubiquitin
play
critic
role
mani
key
cellular
process
mean
varieti
mechan
chang
protein
stabil
modul
protein
activ
promot
disrupt
proteinprotein
interact
central
player
ubiquitin
ub
small
kda
evolutionarili
conserv
protein
sever
protein
relat
ub
sequenc
threedimension
structur
also
identifi
ublik
protein
ubl
neural
precursor
cell
express
development
downregul
sumo
small
ubiquitin
modifi
import
divers
set
signal
pathway
includ
nuclear
transport
autophagi
antivir
pathway
highli
coordin
multistep
enzymat
cascad
ubiquitin
coval
attach
one
ub
intern
lysin
ly
residu
n
termini
rare
target
protein
sequenti
action
ubiquitinactiv
enzym
ubiquitinconjug
enzym
ubiquitin
ligas
fig
first
employ
atp
adenyl
ub
form
highenergi
thioester
bond
ub
ctermin
carboxyl
group
thiol
group
activ
site
cystein
residu
activ
ubiquitin
transfer
cystein
residu
enzym
similar
thioester
linkag
final
ligas
recruit
charg
enzym
facilit
specif
transfer
ub
protein
substrat
importantli
famili
deubiquitin
enzym
dub
catalyz
cleavag
ub
polypeptid
make
revers
process
also
contribut
ub
homeostasi
ligas
divid
hect
homolog
protein
carboxi
terminu
famili
ring
realli
interest
new
gene
famili
ubox
famili
major
differ
among
hect
ligas
form
intermedi
thioester
bond
ub
linkag
substrat
contrast
ring
ubox
ligas
facilit
ub
transfer
enzym
alloster
mechan
ligas
modifi
protein
attach
singl
ub
one
monoubiquitin
ly
residu
multimonoubiquitin
substrat
sequenti
attach
multipl
ub
moieti
assembl
isopeptid
bond
format
ctermin
gli
carboxyl
intern
ly
side
chain
ub
ly
residu
substrat
form
ub
chain
polyubiquitin
ub
seven
ly
residu
potenti
particip
chain
format
common
intens
studi
residu
involv
polyubiquitin
ub
also
form
linear
chain
link
amin
ntermin
methionin
given
essenti
role
ubiquitin
proteasom
system
up
regul
protein
function
surpris
dysfunct
up
compon
implic
occurr
mani
human
patholog
disord
includ
numer
cancer
cardiovascular
diseas
viral
diseas
neurodegen
disord
exampl
encod
hect
ligas
highli
express
lung
breast
colorect
carcinoma
mutat
inactiv
ligas
caus
breast
cancer
predisposit
overexpress
observ
sever
type
cancer
promot
degrad
therefor
develop
inhibitor
target
specif
compon
up
predict
signific
therapeut
potenti
demonstr
clinic
success
proteasom
inhibitor
bortezomib
millennium
pharmaceut
first
drug
target
up
approv
us
food
drug
administr
fda
treatment
relaps
refractori
multipl
myeloma
bortezomib
dipeptidyl
boron
acid
deriv
fig
revers
inhibitor
chymotrypsinlik
activ
proteasom
core
particl
also
clinic
trial
follicular
nonhodgkin
lymphoma
phase
iii
diffus
larg
b
cell
lymphoma
phase
ii
mani
cancer
although
one
would
assum
inhibit
proteasom
block
common
step
up
therefor
nonspecif
interestingli
bortezomib
show
select
cytotox
cancer
cell
compar
normal
cell
probabl
cancer
cell
much
proteasom
workload
may
gener
higher
concentr
aberr
protein
irrevers
proteasom
inhibitor
structur
mechanist
distinct
bortezomib
carfilzomib
onyx
pharmaceut
fig
approv
fda
patient
previous
treat
bortezomib
immunomodulatori
compound
carfilzomib
induc
cell
cycl
arrest
apoptosi
varieti
human
cancer
cell
line
importantli
potent
select
bortezomib
therefor
display
activ
bortezomibresist
cancer
cell
cytotox
rpmi
multipl
myeloma
cell
higher
bortezomib
effort
ongo
develop
secondgener
proteasom
inhibitor
hope
may
yield
drug
display
better
potenc
fewer
side
effect
detail
review
proteasom
inhibitor
synthesi
pharmacolog
clinic
treatment
multipl
myeloma
type
cancer
publish
elsewher
discuss
fig
up
inhibitor
ubiquitin
involv
threestep
enzymat
cascad
first
employ
atp
adenyl
ub
form
highenergi
thioester
bond
ub
ctermin
carboxyl
group
thiol
group
activ
site
cystein
residu
activ
ub
transfer
cystein
residu
enzym
thioester
linkag
final
ligas
recruit
charg
help
transfer
ub
specif
protein
substrat
form
mono
shown
polyub
chain
lead
differ
cellular
respons
includ
signal
event
protein
degrad
proteasom
deubiquitin
enzym
dub
catalyz
cleavag
ub
polypeptid
revers
ubiquitin
process
maintain
ub
homeostasi
b
inhibitor
block
variou
step
ubiquitin
pathway
rapidli
grow
understand
fundament
import
up
cell
signal
diseas
realiz
system
provid
rich
sourc
attract
molecular
target
pharmacolog
intervent
mani
group
compani
gear
search
small
molecul
inhibitor
select
block
certain
step
up
success
bortezomib
carfilzomib
anticanc
therapi
suggest
develop
compound
would
clinic
import
target
individu
pathway
substrat
protein
therapeut
benefit
drug
increas
effect
treatment
also
fewer
nonspecif
side
effect
compar
gener
proteasom
inhibitor
review
illustr
recent
progress
find
specif
inhibitor
up
compon
fig
implic
human
diseas
therefor
repres
potenti
therapeut
target
highlight
invent
ub
variant
technolog
rapid
mean
gener
tool
modul
up
enzym
smallmolecul
inhibitor
target
step
ubiquitin
cascad
ub
activ
ub
activ
enzym
two
member
human
genom
catalyz
first
step
ubiquitin
pathway
atpdepend
manner
first
bind
atp
adenyl
ctermin
glycin
ub
form
coval
thioester
bond
catalyt
cystein
ub
subsequ
bind
second
atp
ub
form
ternari
complex
compet
transfer
thioesterbound
ub
varieti
ub
conjug
enzym
biochem
three
major
point
ub
activ
target
inhibit
first
bind
atp
enzym
may
block
use
atpcompetit
smallmolecul
inhibitor
analog
use
inhibit
kinas
second
format
coval
complex
may
prevent
target
activesit
thiol
third
interact
enzym
may
block
howev
inhibit
ub
activ
predict
nonspecif
principl
requir
ubiquitin
mani
substrat
cell
inde
temperaturesensit
mutat
arrest
cell
cycl
late
phase
indic
multipl
pathway
requir
cell
prolifer
normal
cell
affect
mutat
summar
advanc
develop
inhibitor
ub
enzym
fig
ub
inhibitor
fig
irrevers
pyrazon
deriv
inhibitor
identifi
screen
inhibitor
ubiquitin
found
nitrogen
dioxid
group
furan
ring
like
block
catalyt
cystein
ub
importantli
compound
demonstr
inhibitori
activ
thioldepend
enzym
includ
sever
enzym
howev
partial
inhibit
hect
ligas
activ
vitro
rais
specif
concern
effect
cell
treat
includ
inhibit
cytokineinduc
nuclear
factor
jb
nfjb
activ
stabil
protein
level
induct
transcript
preferenti
kill
transform
cell
wildtyp
wt
interestingli
treatment
caus
increas
cellular
sumoyl
neddyl
level
stay
potenti
therapeut
valu
target
ub
underscor
unexpect
find
nitric
oxid
produc
prodrug
jsk
fig
inhibit
thioester
format
interact
ub
activesit
thiol
consist
ub
inhibitor
downstream
effect
jsk
treatment
includ
decreas
level
total
ubiquitin
protein
increas
express
interestingli
ubl
protein
found
requir
activ
larg
subfamili
ligas
cullinr
ligas
crl
protein
share
sequenc
ident
ub
also
conjug
protein
process
initi
specif
nae
activ
enzym
therefor
inhibit
nae
would
specif
inhibit
ub
mani
crl
substrat
import
regul
cancer
cell
growth
surviv
includ
cell
cycl
inhibitor
inhibit
pathway
recent
demonstr
use
smallmolecul
inhibitor
fig
adenosin
sulfam
analog
bind
nucleotidebind
pocket
thioester
nae
form
coval
adduct
effect
deplet
neddlyat
activ
substrateassist
inhibit
therebi
drive
crl
inact
nonneddyl
form
shown
mous
cancer
model
appear
exert
effect
stabil
dna
replic
licens
factor
substrat
scf
ligas
lead
dna
synthesi
misregul
apoptosi
senesc
prolifer
cancer
cell
preclin
data
show
high
efficaci
diffus
larg
b
cell
lymphoma
acut
myeloid
leukemia
aml
compound
enter
phase
iii
clinic
trial
treatment
multipl
myeloma
nonhodgkin
lymphoma
notabl
analogu
form
similar
adduct
ubl
protein
inhibit
cognat
enzym
includ
ub
sumoactiv
enzym
indic
substrateassist
inhibit
may
prove
use
target
ubl
pathway
second
step
ubiquitin
cascad
control
ub
conjug
enzym
member
human
genom
ubl
protein
also
specif
enzym
sumo
review
enzym
link
cancer
diseas
includ
head
neck
carcinoma
lung
cancer
chromosom
instabl
tumor
format
enzym
accept
activ
ub
thioester
bond
catalyt
cystein
transfer
ub
substrat
protein
assist
ligas
enzym
catalyz
ub
chain
initi
elong
case
also
govern
type
extent
ub
linkag
howev
enzym
function
specif
step
demonstr
chain
initi
substrat
chain
elong
mediat
process
yeast
catalyt
properti
enzym
bind
ub
mediat
highli
conserv
amino
acid
ubconjug
catalyt
domain
ubc
enzym
classifi
base
presenc
ctermin
extens
catalyt
core
import
function
implic
enzym
interact
multipl
ligas
exampl
recogn
sever
scf
complex
also
shown
network
interact
studi
pair
therefor
target
ub
conjug
inhibit
interact
interfac
may
provid
better
specif
target
interfac
dedic
enzym
crl
ligas
promot
polyubiquitin
degrad
cell
cycl
regulatori
protein
includ
cell
cycl
inhibitor
function
prevent
progress
highthroughput
screen
inhibit
ubiquitin
sicheri
group
found
small
molecul
name
fig
turn
specif
inhibitor
human
fig
homolog
yeast
counterpart
inhibitor
act
alloster
bind
pocket
away
activ
site
induc
number
transloc
secondari
structur
element
enzym
fig
close
relat
deriv
caus
accumul
cyclin
e
cell
inhibit
prolifer
human
cancer
cell
find
suggest
may
feasibl
develop
highli
select
inhibitor
enzym
similar
manner
final
step
ubiquitin
control
ub
ligas
member
human
genom
determin
select
ubiquitin
interact
substrat
ub
transfer
inhibitor
interact
may
thu
enabl
specif
target
limit
number
protein
may
translat
better
therapeut
ratio
fewer
side
effect
end
structur
studi
ligas
substratebind
surfac
site
mediat
ubiquitin
activ
assembl
complex
reveal
molecular
mechan
also
facilit
discoveri
smallmolecul
inhibitor
discuss
ligas
function
one
two
gener
mechan
either
form
coval
ub
adduct
activ
site
hect
serv
noncoval
adaptor
facilit
transfer
ub
substrat
ring
ubox
three
class
ligas
differ
protein
interact
domain
hect
ring
ubox
bind
enzym
domain
recruit
substrat
hect
domain
polypeptid
adopt
bilob
structur
ntermin
lobe
contain
site
ctermin
lobe
harbor
catalyt
cystein
lobe
separ
small
linker
stretch
form
cleft
activ
site
howev
surfac
quit
shallow
well
adapt
target
small
molecul
hand
ring
finger
domain
form
conserv
pattern
cystein
histidin
residu
hold
two
zn
ion
conform
refer
crossbrac
motif
bind
enzym
final
ringlik
ubox
famili
adopt
similar
structur
without
employ
zn
coordin
one
might
think
inhibit
canon
catalyt
site
hect
would
easier
target
proteinprotein
interact
domain
ring
ubox
report
small
molecul
inhibitor
ligas
target
ringtyp
enzym
fig
stabil
tumor
suppressor
critic
cell
respond
stress
limit
cancer
develop
ring
ligas
crucial
role
regul
abund
mani
tumor
retain
wild
type
show
evid
overexpress
thu
target
cancer
cell
attract
strategi
cancer
therapi
nutlin
imidazolin
deriv
develop
roch
first
group
small
molecul
interfer
abil
mediat
ubiquitin
fig
disrupt
interact
bind
directli
site
therebi
stabil
inde
nutlin
induc
cellcycl
arrest
apoptosi
cellular
senesc
cancer
cell
line
importantli
nutlin
signific
antitumor
effect
shown
growth
inhibit
human
tumor
xenograft
mice
obviou
toxic
healthi
tissu
nutlin
fig
advanc
clinic
trial
solid
tumor
leukemia
given
favor
preclin
characterist
term
pharmacolog
properti
toxic
rita
fig
anoth
small
molecul
shown
regul
interact
chemic
screen
design
find
compound
specif
arrest
growth
cancer
cell
line
instead
bind
rita
probabl
bind
nterminu
therebi
induc
conform
chang
stabil
ntermin
ahelix
prevent
recognit
interestingli
rita
affect
transcript
activ
rather
prevent
interact
regulatori
protein
parc
parkinlik
cytoplasm
protein
promot
polyubiquitin
nutlin
rita
induc
apoptosi
human
tumor
cell
littl
effect
normal
cell
slow
growth
tumour
xenograft
mice
interest
test
whether
rita
nutlin
act
synergist
induc
apoptosi
cancer
cell
inhibitor
ligas
activ
also
report
abl
promot
stabil
activ
studi
requir
determin
whether
molecul
use
treatment
human
cancer
anoth
class
ring
ligas
activ
target
field
iap
inhibitorofapoptosi
protein
sever
antagonist
iap
fig
alreadi
enter
clinic
trial
varieti
cell
line
iap
effect
suppress
enzymat
activ
caspas
therefor
inhibit
apoptosi
mediat
intrins
extrins
pathway
includ
death
receptor
activ
ioniz
radiat
viral
infect
ligas
activ
iap
key
regulatori
compon
apoptot
program
sinc
mediat
autoubiquitin
degrad
also
substrat
smac
protein
interact
surfac
groov
domain
iap
prevent
iap
inhibit
initi
effector
caspas
small
molecul
mimic
smac
found
bind
cellular
iap
potent
induc
caspas
activ
apoptosi
human
cancer
cell
studi
smac
mimet
small
molecul
reveal
induc
autoubiquitin
degrad
iap
lead
death
cancer
cell
stimul
tumor
necrosi
factor
tnfa
pathway
small
molecul
inhibitor
sever
scf
famili
member
crl
ligas
also
identifi
scf
complex
compos
modular
core
contain
scaffold
ring
domain
contain
protein
ubiquitin
substrat
specif
modul
compos
member
fbox
famili
protein
mani
overexpress
mani
cancer
correl
poor
prognosi
case
scf
complex
inhibit
either
fbox
proteinsubstr
interfac
recruit
fbox
protein
scf
core
attract
strategi
select
inhibit
ubiquitin
event
scf
ubiquitin
target
proteasom
destruct
decreas
level
poor
prognosi
factor
mani
malign
research
identifi
small
molecul
cpda
fig
prevent
incorpor
scf
complex
thu
induc
cell
cycl
arrest
stabil
substrat
importantli
cpda
sensit
multipl
myeloma
cell
bortezomib
activ
myeloid
lymphoblastoid
leukemia
cell
deriv
patient
addit
recent
studi
screen
inhibitor
select
target
interfac
form
approach
yield
four
compound
stabil
express
differ
cancer
cell
line
induc
cell
cycl
arrest
scf
crl
ligas
trigger
degrad
ikba
inhibitori
compon
transcript
factor
nfkb
inhibitor
scf
may
therefor
potenti
prevent
polyubiquitin
degrad
ikba
research
also
identifi
smallmolecul
inhibitor
yeast
ortholog
mammalian
fbox
protein
f
box
wd
repeat
domaincontain
structur
studi
reveal
inhibitor
name
fig
insert
bstrand
domain
remot
substratebind
site
fig
bind
induc
seri
conform
chang
distort
substratebind
pocket
impair
bind
ubiquitin
substrat
phosphoryl
inhibitor
thu
one
first
alloster
inhibitor
ligas
identifi
thu
far
discoveri
rais
possibl
similar
strategi
alloster
modul
class
protein
small
molecul
inhibit
scf
close
relat
scf
recent
identifi
chemic
genet
screen
yeast
enhanc
rapamycin
compound
fig
bound
fbox
protein
diminish
bind
vivo
therebi
disrupt
assembl
function
scf
complex
stabil
substrat
final
drug
thalidomid
sed
caus
birth
effect
identifi
inhibitor
cereblon
crbn
compon
complex
import
limb
outgrowth
express
fibroblast
growth
factor
embryon
develop
collect
proofofprincipl
studi
demonstr
feasibl
obtain
select
pharmacolog
inhibitor
scf
ligas
offer
highli
specif
therapeut
approach
wide
varieti
malign
gener
ub
chain
homogen
residu
modifi
elong
although
mix
linkag
chain
observ
mass
spectrometri
studi
reveal
seven
ly
residu
ntermin
met
residu
particip
format
ub
linkag
interestingli
differ
linkag
result
differ
chain
topolog
shown
structur
diub
molecul
ub
chain
adopt
either
compact
conform
adjac
moieti
interact
eg
linkag
open
conform
interfac
present
except
linkag
site
eg
linkag
differ
chain
topolog
like
determin
fate
ubiquitin
protein
instanc
protein
tag
polyub
chain
gener
label
proteasomemedi
recognit
protein
degrad
contrast
polyub
chain
implic
varieti
nonproteolyt
function
includ
dna
repair
protein
traffick
ribosom
protein
synthesi
role
type
ub
chain
studi
great
detail
chain
specif
role
start
emerg
exampl
chain
highli
abund
mitot
cell
anaphasepromot
complex
cyclosom
apcc
key
cell
cycl
regul
degrad
substrat
chain
also
play
import
role
endoplasm
reticulumassoci
degrad
nfjb
essenti
modul
nemo
depend
activ
nfjb
linkag
assembl
ubox
ligas
stress
respons
chain
play
role
ub
fusion
degrad
chain
like
proteolyt
role
linear
chain
assembl
linear
ubiquitin
chain
assembl
complex
play
crucial
role
nfjb
signal
unexpectedli
recent
largescal
chemic
genet
screen
identifi
small
molecul
known
ubistatin
fig
ubistatin
specif
bind
ubiquitin
chain
reconstitut
vitro
system
ubistatin
stabil
cyclin
b
substrat
apcc
scf
respect
nmr
vitro
bind
assay
show
ubistatin
bind
interfac
ub
molecul
therebi
chang
conform
ub
chain
impair
bind
recognit
polyub
receptor
proteasom
molecul
strong
neg
charg
therefor
cell
permeabl
provid
evid
new
therapeut
approach
block
protein
degrad
modif
polyub
chain
recent
year
revers
ubiquitin
attract
increas
attent
crucial
mediat
within
intracellular
signal
nfjb
pathway
revers
accomplish
deubiquitin
enzym
dub
remov
ub
moieti
substrat
prevent
protein
degrad
signal
dub
also
contribut
ub
homeostasi
edit
form
modif
trim
ub
chain
therefor
surpris
misregul
dub
implic
grow
number
diseas
includ
neurolog
disord
viral
infect
cancer
human
approxim
dub
belong
five
differ
structur
famili
approxim
ubiquitin
specif
proteas
usp
four
ubiquitin
ctermin
hydrolas
uch
four
josephin
domain
machadojoseph
diseas
protein
domain
proteas
ovarian
tumor
otu
proteas
eight
domain
jamm
metalloenzym
proteas
well
accept
dub
famili
enzym
druggabl
demonstr
high
degre
substrat
specif
contain
well
defin
catalyt
pocket
make
amen
screen
librari
small
molecul
inde
inhibitor
uch
famili
dub
report
modest
select
affin
encouragingli
good
progress
develop
small
molecul
inhibitor
target
sar
cov
sever
acut
respiratori
syndrom
coronaviru
dub
plpro
papainlik
proteas
confirm
potenti
dub
famili
one
druggabl
famili
up
novarti
patent
compound
inhibit
implic
pathway
neurodegen
disord
respect
summar
recent
advanc
develop
inhibitor
usp
fig
intens
studi
subfamili
dub
recent
found
deubiquitin
inhibitor
dna
bind
id
protein
consequ
promot
stem
cell
characterist
osteosarcoma
mrna
protein
level
also
increas
subset
human
osteosarcoma
biopsi
sampl
final
knockdown
osteosarcoma
cell
caus
cellcycl
arrest
osteogen
differenti
interestingli
also
deubiquitin
central
player
fanconi
anemia
fa
pathway
requir
foci
format
releas
chromatin
essenti
function
dna
repair
therefor
promis
target
pharmacolog
intervent
inhibit
proteas
activ
malign
osteosarcoma
lead
reduc
prolif
capac
potenti
revers
transform
phenotyp
defect
dna
repair
sensit
cell
chemotherapeut
agent
note
form
stabl
complex
stimul
catalyt
activ
recent
cell
activ
smallmolecul
revers
inhibitor
identifi
pimozid
fig
display
select
number
dub
desumoylas
cystein
proteas
studi
inhibitor
suggest
pimozid
inhibit
noncompetit
mechan
bind
site
activ
site
importantli
inhibitor
act
synergist
chemotherapi
drug
cisplatin
inhibit
prolifer
cisplatinresist
nonsmal
cell
lung
cancer
nsclc
cell
howev
biochem
genet
studi
osteosarcoma
cell
treat
inhibitor
critic
assess
therapeut
potenti
key
regul
well
mani
substrat
involv
variou
cellular
pathway
discuss
ligas
bind
ubiquitin
regul
cellular
protein
level
activ
critic
compon
pathway
deubiquitin
stabil
shown
gu
group
partial
reduct
level
sever
human
cell
line
promot
decreas
level
yet
total
abolit
stabil
level
decreas
observ
suggest
absenc
promot
downregul
turn
elimin
activ
ub
ligas
hybrigen
develop
cyanoindenopyrazin
deriv
small
molecul
compound
fig
inhibit
activ
submicromolar
rang
quit
select
panel
cystein
proteas
kinet
data
indic
hbx
uncompetit
revers
inhibitor
alloster
modul
catalyt
reaction
similar
rnaimedi
silenc
cancer
cell
treatment
stabil
activ
transcript
target
gene
without
induc
genotox
stress
inhibit
cancer
cell
growth
recent
inhibitor
develop
like
help
character
potenti
inhibitor
preclin
set
instanc
hybrigen
develop
secondgener
irrevers
inhibitor
fig
capabl
regul
substrat
cancer
cell
recapitul
knockdown
phenotyp
inde
incub
exponenti
grow
cell
hbx
led
increas
level
target
protein
cyclindepend
kinas
inhibitor
importantli
bind
select
activ
site
much
specif
anoth
select
inhibitor
fig
abl
induc
apoptosi
multipl
myeloma
cell
resist
convent
bortezomib
therapi
discuss
proteasom
major
regul
ubmedi
protein
degrad
one
three
human
dub
along
associ
regulatori
particl
multisubunit
proteasom
ntermin
ubl
domain
requir
associ
proteasom
associ
stimul
catalyt
activ
shown
inhibit
degrad
ubprotein
conjug
vitro
cell
trim
ub
chain
substrat
recent
highthroughput
screen
identifi
select
revers
smallmolecul
inhibitor
deubiquitin
activ
human
compound
fig
bind
specif
activ
form
proteasom
bound
enhanc
degrad
sever
proteasom
substrat
cell
includ
implic
neurodegen
diseas
ie
tau
suggest
potenti
strategi
reduc
level
misfold
aggreg
protein
cell
proteotox
stress
devis
inhibitor
design
strategi
base
fact
enzym
protein
interact
ub
recogn
common
surfac
low
affin
high
specif
exampl
although
catalyt
domain
usp
often
share
low
sequenc
homolog
crystal
structur
reveal
common
ubbind
site
differ
usp
ub
bound
orient
isopeptid
linkag
align
activ
site
interestingli
interact
surfac
side
larg
bind
gener
weak
howev
despit
common
fold
ubbind
site
usp
famili
member
differ
sequenc
consequ
exhibit
signific
topolog
variat
importantli
paradigm
weak
interact
larg
divers
surfac
also
extend
ubbind
protein
up
includ
enzym
ligas
ubbind
domain
ubd
base
observ
reason
possibl
use
ub
scaffold
engin
high
affin
binder
virtual
ubinteract
protein
would
accomplish
introduc
mutat
ub
surfac
would
enhanc
bind
toward
particular
protein
sinc
ubbind
site
larg
variabl
strategi
produc
ub
variant
ubv
bind
tightli
specif
importantli
ubv
act
potent
modul
up
protein
block
bind
low
affin
ub
substrat
natur
bind
site
display
ub
bacteriophag
identifi
residu
make
contact
usp
surfac
constitut
uspbind
site
fig
construct
librari
simultan
target
entir
uspbind
site
combinatori
mutagenesi
use
three
mutagen
oligonucleotid
cover
contigu
region
primari
sequenc
use
soft
random
strategi
librari
bias
favor
wt
sequenc
allow
signific
divers
across
entir
uspbind
surfac
reason
would
enabl
select
variant
mutat
improv
affin
particular
usp
without
drastic
alter
bind
site
librari
use
perform
phage
display
select
fig
yield
usp
inhibitor
also
inhibitor
even
activ
dub
ub
ligas
ubd
implic
ubiquitin
remodel
clathrinmedi
intern
endosom
sort
regul
receptor
tyrosin
kinas
includ
epiderm
growth
factor
receptor
egfr
identifi
ubv
bound
specif
ubbind
site
fig
inhibit
catalyt
activ
potenc
singledigit
nanomolar
rang
interestingli
bind
noncanon
fashion
inhibit
function
stabil
autoinhibit
state
activ
site
held
close
conform
cell
interact
caus
ubiquitin
lyososom
local
downregul
activ
endogen
egfr
expect
outcom
inhibit
also
identifi
ubv
target
ubbind
site
fig
fig
other
identifi
inhibitor
ubiquitin
receptorinteract
protein
posit
regul
nfjb
activ
induc
tnfa
turn
shown
downregul
tnfainduc
nfjb
activ
deubiquitin
identifi
ubv
inhibit
singledigit
nanomolar
potenc
block
deubiquitin
restor
nfjb
activ
show
act
inhibitor
cell
final
complex
structur
ubv
bind
manner
similar
wild
type
ub
mutat
lead
improv
hydrophob
contact
rewir
hydrogen
bond
network
extend
beyond
usp
ubv
librari
also
yield
inhibitor
member
otu
dub
famili
requir
clearanc
ub
conjug
dna
damag
effici
inhibit
catalyz
cleavag
diub
also
bind
activ
enzym
bind
enhanc
presenc
ub
although
bind
much
tightli
wt
ub
show
compromis
abil
promot
complex
format
suggest
alter
bind
mode
inde
structur
complex
reveal
inhibitor
bind
distal
ub
bind
site
enabl
ration
alter
bind
alloster
properti
fig
although
hect
ligas
play
critic
role
cancer
possess
intrins
catalyt
activ
make
potenti
target
drug
develop
small
molecul
inhibitor
yet
identifi
famili
member
use
ubv
librari
success
gener
specif
binder
itch
surprisingli
binder
act
activ
increas
autoubiquitin
vitro
activ
activ
also
observ
cell
increas
ubiquitin
yinyang
protein
known
substrat
unexpect
result
underscor
need
ligand
act
directli
discret
ubbind
site
confirm
refin
effect
observ
rnai
approach
work
reduc
level
entir
protein
moreov
result
demonstr
engin
ub
variant
also
util
activ
protein
up
togeth
alreadi
establish
inhibit
dub
repres
gener
strategi
could
use
develop
enzym
modul
studi
up
systemwid
scale
past
decad
ub
taken
center
stage
cell
signal
clear
humbl
protein
play
lead
role
control
numer
signal
pathway
consequ
enzym
drive
ubiquitin
deubiquitin
attract
consider
interest
potenti
target
treatment
cancer
diseas
research
protein
phosphoryl
driven
target
cancer
therapi
last
decad
hope
high
basic
discoveri
ub
biolog
yield
new
class
therapi
upcom
decad
unfortun
hope
thu
far
stymi
pauciti
specif
inhibitor
ubiquitin
deubiquitin
pathway
nonetheless
recent
develop
smallmolecul
chemistri
protein
engin
provid
hope
inhibitor
design
protein
up
may
enter
acceler
phase
follow
develop
clinic
success
proteasom
inhibitor
signific
progress
made
identifi
small
molecul
target
specif
up
compon
fig
potenti
treatment
diseas
cancer
neurodegen
diseas
compound
yet
enter
clinic
trial
face
ultim
test
therapeut
efficaci
human
nevertheless
proofsofprincipl
show
feasibl
select
inhibit
mani
step
ubiquitin
pathway
noteworthi
unlik
atpcompetit
inhibitor
kinas
gener
smallmolecul
approach
avail
inhibit
dub
therefor
custom
design
highthroughput
screen
strategi
remain
crucial
smallmolecul
inhibitor
discoveri
parallel
small
molecul
develop
ubv
deriv
protein
engin
shown
ideal
tool
convent
cell
biolog
experi
elucid
molecular
mechan
biolog
function
ub
ligas
dub
recombin
natur
ubv
enabl
facil
manipul
genet
level
adapt
protein
differ
assay
applic
ubv
directli
target
function
site
act
potent
specif
inhibitor
activ
catalyt
function
consequ
use
assess
directli
effect
activ
site
inhibit
valid
up
enzym
drug
target
therapi
cancer
diseas
moreov
insight
structur
studi
may
applic
design
mechanismbas
therapeut
small
molecul
inhibitor
